Trial Profile
An international randomized phase III study of first-line erlotinib followed by second-line cisplatin + gemcitabine versus first-line cisplatin + gemcitabine followed by second-line erlotinib in advanced non small cell lung cancer
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Erlotinib (Primary) ; Cisplatin; Gemcitabine
- Indications Non-small cell lung cancer
- Focus Biomarker; Therapeutic Use
- Acronyms TORCH
- 31 May 2013 Results of an economic analysis in Canada presented at the 49th Annual Meeting of the American Society of Clinical Oncology.
- 09 Jul 2012 Results published in the Journal of Clinical Oncology.
- 17 Jun 2010 Status changed from active, no longer recruiting to discontinued.